Doximity/$DOCS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Doximity
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
- Ticker
- $DOCS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 880
- Headquarters
- San Francisco, United States
- Website
- www.doximity.com
Doximity Metrics
BasicAdvanced
$5.5B
36.29
$0.84
1.21
-
Price and volume
Market cap
$5.5B
Beta
1.21
52-week high
$71.37
52-week low
$17.15
Average daily volume
3M
Financial strength
Current ratio
6.078
Quick ratio
5.796
Long term debt to equity
0.008
Total debt to equity
0.011
Profitability
EBITDA (TTM)
208.403
Gross margin (TTM)
88.07%
Net profit margin (TTM)
25.48%
Operating margin (TTM)
30.57%
Effective tax rate (TTM)
26.16%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
10.95%
Return on equity (TTM)
17.21%
Valuation
Price to earnings (TTM)
36.294
Price to revenue (TTM)
8.66
Price to book
6
Price to tangible book (TTM)
6.89
Price to free cash flow (TTM)
19.119
Free cash flow yield (TTM)
5.23%
Free cash flow per share (TTM)
1.599
Growth
Revenue change (TTM)
11.18%
Earnings per share change (TTM)
-27.94%
3-year revenue growth (CAGR)
14.49%
3-year earnings per share growth (CAGR)
14.56%
What the Analysts think about Doximity
Analyst ratings (Buy, Hold, Sell) for Doximity stock.
Analyst projections of the future price of Doximity stock.
Bulls say / Bears say
Workflow active prescribers grew more than 30% year on year, nearly half used Doximity’s AI tools, and Scribe users were up tenfold year on year in July. This growing use gives Doximity a wider base from which to sell workflow and AI services. (Fierce Healthcare)
Doximity Ask ranked as the top-performing U.S.-based model in the NOHARM clinical safety benchmark. That gives its clinical AI suite evidence of quality that could help it win physician and health-system adoption. (Morningstar)
AI Search attracted its first cohort of pharmaceutical programmes, with most of the contracted revenue expected to be recognised in fiscal Q3. That offers a route to turn strong physician engagement into a new source of sales. (Biggo, The Motley Fool)
Q1 revenue rose, but GAAP net income fell 54% and adjusted EBITDA fell 6% year on year; adjusted EBITDA margin also dropped to 47.7% from 54.7%. Higher AI and operating costs risk making it harder to sustain Doximity’s strong profitability. (Morningstar)
Management described the digital pharma advertising market as soft and expected it to grow at or below 5% amid policy and economic uncertainty. Continued budget caution could weigh on the core marketing business before new AI products generate meaningful sales. (StockStory)
Just 127 large customers generated 83% of revenue, while overall net revenue retention was 107%. This concentration leaves growth exposed if a few major customers reduce spending or stop expanding their subscriptions. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
Doximity Financial Performance
Revenues and expenses
Doximity Earnings Performance
Company profitability
Upcoming events
No upcoming events
Doximity News
AllArticlesVideos
ROSEN, A LONGSTANDING FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
Newsfile Corp20 hours ago
Kaplan Fox Reminds Investors of a Securities Class Action Against Doximity, Inc. (DOCS) - Deadline is November 16, 2026
Newsfile Corp1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCS
Newsfile Corp2 days ago
Funds containing Doximity
AllUSDGBPEUR
Fund name | Fund size | $DOCS weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.11% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.11% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.05% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.